Featured

TrumpRx website launches with drug discounts but insurance customers should check fine print first

TLDR:

  • Trump’s new TrumpRx website launches this month, offering drugs at 40-80% discounts by cutting out insurance middlemen
  • President believes the program will be a midterm election game-changer: “We should win the elections on just that thing”
  • Insured patients may actually lose money using the site by forfeiting deductible credits and insurer-negotiated prices
  • Target customers are 27.2 million uninsured Americans and 80+ million in high-deductible plans who pay full price anyway

President Trump is betting his new prescription drug website will deliver a political windfall in the midterms, but health experts warn insured Americans to read the fine print before ditching their coverage.

TrumpRx.gov, set to launch this month, allows consumers to purchase medications directly from 14 major pharmaceutical companies at steep discounts — Ozempic drops from $1,000 to $350 monthly, for instance.

“We should win the elections on just that thing,” Mr. Trump recently said of the program.

But the political upside comes with consumer caveats. Insured patients who use TrumpRx forfeit benefits like deductible credits and prices their insurers already negotiated.

“Most people with insurance coverage will continue to be better off using their insurance,” said Juliette Cubanski, deputy director of Medicare policy at KFF. “You just have to kind of understand the caveats.”

The real beneficiaries: 27.2 million uninsured Americans and over 80 million enrolled in high-deductible plans who pay full price anyway.

White House spokesman Kush Desai said the discounts “will yield billions in annual savings for American patients.”

The program wasn’t passed by Congress, leaving its future uncertain beyond 2028.

Read more:

Art of the drug deal: TrumpRX website will direct patients to heavily discounted medicines


This article is written with the assistance of generative artificial intelligence based solely on Washington Times original reporting and wire services. For more information, please read our AI policy or contact Steve Fink, Director of Artificial Intelligence, at sfink@washingtontimes.com


The Washington Times AI Ethics Newsroom Committee can be reached at aispotlight@washingtontimes.com.

Source link

Related Posts

1 of 1,261